Emerging drugs for irritable bowel syndrome.
Irritable bowel syndrome is extremely common and its severity is widely underestimated. Unfortunately, the current pharmacological treatment of this condition is far from satisfactory which might suggest that it would be an area in which the pharmaceutical industry would take a great interest. However, drug development in this field, especially in relation to 5-hydroxytryptamine (5-HT), has been beset by difficulties with side effects and, what some authorities would claim, an unnecessarily strict regulatory climate based on the perception that irritable bowel syndrome is not a particularly serious condition. This has resulted in a rapid withdrawal from the scene by a number of companies although with the identification of some potential new therapeutic targets, the area has not been totally abandoned.
Shekhar
Chander
C
University of Manchester, Neurogastroenterology Unit, University Hospital of South Manchester NHS Trust, Manchester, M23 9LT, UK. peter.whorwell@UHSM.NHS.UK
Whorwell
Peter J
PJ
D015195:Drug Design; D004345:Drug Industry; D005765:Gastrointestinal Agents / Q000009:adverse effects; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000628:therapy; D012701:Serotonin / Q000009:adverse effects*; D016896:Treatment Outcome
D005765:Gastrointestinal Agents; D012701:Serotonin